(USNA) USANA Health Sciences - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US90328M1071
Stock:
Total Rating 32
Risk 73
Buy Signal -0.32
| Risk 5d forecast | |
|---|---|
| Volatility | 40.3% |
| Relative Tail Risk | -10.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.47 |
| Alpha | -52.12 |
| Character TTM | |
|---|---|
| Beta | 1.014 |
| Beta Downside | 1.077 |
| Drawdowns 3y | |
|---|---|
| Max DD | 72.51% |
| CAGR/Max DD | -0.42 |
EPS (Earnings per Share)
Revenue
Description: USNA USANA Health Sciences
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. It operates in two segments, Direct selling and Hiya Direct-To-Consumer. The company offers USANA nutritional optimizers, including supplements for cardiovascular health, skeletal/structural health, and digestive health; Essentials/CellSentials, such as vitamin and mineral supplements for age group beginning with children 13 months of age; and food products that include meal replacement shakes, snack bars, and other related products for healthy weight management, digestive health, and energy and hydration. It also provides Celavive, a skincare regimen for various skin care types and ethnicities; and all other products comprising materials and online tools for associates to build business and marketing of products The company sells its products through retail customers, a subscription model, and direct selling, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 10.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -6.26 > 1.0 |
| NWC/Revenue: 17.28% < 20% (prev 16.33%; Δ 0.94% < -1%) |
| CFO/TA 0.04 > 3% & CFO 31.5m > Net Income 10.8m |
| Net Debt (-144.4m) to EBITDA (95.0m): -1.52 < 3 |
| Current Ratio: 2.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (18.3m) vs 12m ago -4.20% < -2% |
| Gross Margin: 78.29% > 18% (prev 0.79%; Δ 7750 % > 0.5%) |
| Asset Turnover: 124.1% > 50% (prev 114.2%; Δ 9.89% > 0%) |
| Interest Coverage Ratio: 65.70 > 6 (EBITDA TTM 95.0m / Interest Expense TTM 842.0k) |
Altman Z'' 7.53
| A: 0.22 (Total Current Assets 288.4m - Total Current Liabilities 128.6m) / Total Assets 742.9m |
| B: 0.63 (Retained Earnings 467.5m / Total Assets 742.9m) |
| C: 0.07 (EBIT TTM 55.3m / Avg Total Assets 745.6m) |
| D: 3.40 (Book Value of Equity 533.1m / Total Liabilities 156.6m) |
| Altman-Z'' Score: 7.53 = AAA |
Beneish M
| DSRI: none (Receivables none/8.22m, Revenue 925.3m/854.5m) |
| GMI: 1.01 (GM 78.29% / 79.43%) |
| AQI: 0.97 (AQ_t 0.48 / AQ_t-1 0.50) |
| SGI: 1.08 (Revenue 925.3m / 854.5m) |
| TATA: -0.03 (NI 10.8m - CFO 31.5m) / TA 742.9m) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of USNA shares?
As of February 28, 2026, the stock is trading at USD 21.52 with a total of 111,665 shares traded.
Over the past week, the price has changed by -0.69%, over one month by -2.80%, over three months by +8.41% and over the past year by -24.86%.
Over the past week, the price has changed by -0.69%, over one month by -2.80%, over three months by +8.41% and over the past year by -24.86%.
Is USNA a buy, sell or hold?
USANA Health Sciences has received a consensus analysts rating of 3.00.
Therefor, it is recommend to hold USNA.
- StrongBuy: 0
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the USNA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 39 | 81.2% |
| Analysts Target Price | 39 | 81.2% |
USNA Fundamental Data Overview February 24, 2026
P/E Trailing = 24.0778
P/E Forward = 11.919
P/S = 0.4281
P/B = 0.9441
P/EG = 0.9381
Revenue TTM = 925.3m USD
EBIT TTM = 55.3m USD
EBITDA TTM = 95.0m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 14.0m USD (from shortTermDebt, last quarter)
Debt = 14.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -144.4m USD (from netDebt column, last quarter)
Enterprise Value = 251.8m USD (396.1m + Debt 14.0m - CCE 158.4m)
Interest Coverage Ratio = 65.70 (Ebit TTM 55.3m / Interest Expense TTM 842.0k)
EV/FCF = 13.47x (Enterprise Value 251.8m / FCF TTM 18.7m)
FCF Yield = 7.43% (FCF TTM 18.7m / Enterprise Value 251.8m)
FCF Margin = 2.02% (FCF TTM 18.7m / Revenue TTM 925.3m)
Net Margin = 1.16% (Net Income TTM 10.8m / Revenue TTM 925.3m)
Gross Margin = 78.29% ((Revenue TTM 925.3m - Cost of Revenue TTM 200.9m) / Revenue TTM)
Gross Margin QoQ = 88.77% (prev 73.45%)
Tobins Q-Ratio = 0.34 (Enterprise Value 251.8m / Total Assets 742.9m)
Interest Expense / Debt = 0.88% (Interest Expense 123.0k / Debt 14.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = 43.7m (EBIT 55.3m * (1 - 21.00%))
Current Ratio = 2.24 (Total Current Assets 288.4m / Total Current Liabilities 128.6m)
Debt / Equity = 0.03 (Debt 14.0m / totalStockholderEquity, last quarter 533.1m)
Debt / EBITDA = -1.52 (Net Debt -144.4m / EBITDA 95.0m)
Debt / FCF = -7.72 (Net Debt -144.4m / FCF TTM 18.7m)
Total Stockholder Equity = 530.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.44% (Net Income 10.8m / Total Assets 742.9m)
RoE = 2.03% (Net Income TTM 10.8m / Total Stockholder Equity 530.5m)
RoCE = 10.43% (EBIT 55.3m / Capital Employed (Equity 530.5m + L.T.Debt 0.0))
RoIC = 8.13% (NOPAT 43.7m / Invested Capital 537.3m)
WACC = 9.34% (E(396.1m)/V(410.1m) * Re(9.65%) + D(14.0m)/V(410.1m) * Rd(0.88%) * (1-Tc(0.21)))
Discount Rate = 9.65% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.50%
[DCF] Terminal Value 70.73% ; FCFF base≈37.5m ; Y1≈32.6m ; Y5≈26.0m
[DCF] Fair Price = 28.46 (EV 375.9m - Net Debt -144.4m = Equity 520.3m / Shares 18.3m; r=9.34% [WACC]; 5y FCF grow -16.00% → 2.90% )
EPS Correlation: -59.65 | EPS CAGR: -15.93% | SUE: 0.51 | # QB: 0
Revenue Correlation: -54.16 | Revenue CAGR: -4.88% | SUE: 0.04 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.44 | Chg7d=+0.040 | Chg30d=+0.040 | Revisions Net=-1 | Analysts=1
EPS current Year (2026-12-31): EPS=2.00 | Chg7d=+0.160 | Chg30d=+0.050 | Revisions Net=-1 | Growth EPS=+3.6% | Growth Revenue=+1.8%
EPS next Year (2027-12-31): EPS=2.77 | Chg7d=+0.000 | Chg30d=-0.040 | Revisions Net=+1 | Growth EPS=+38.5% | Growth Revenue=+6.2%
P/E Forward = 11.919
P/S = 0.4281
P/B = 0.9441
P/EG = 0.9381
Revenue TTM = 925.3m USD
EBIT TTM = 55.3m USD
EBITDA TTM = 95.0m USD
Long Term Debt = unknown (0.0)
Short Term Debt = 14.0m USD (from shortTermDebt, last quarter)
Debt = 14.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -144.4m USD (from netDebt column, last quarter)
Enterprise Value = 251.8m USD (396.1m + Debt 14.0m - CCE 158.4m)
Interest Coverage Ratio = 65.70 (Ebit TTM 55.3m / Interest Expense TTM 842.0k)
EV/FCF = 13.47x (Enterprise Value 251.8m / FCF TTM 18.7m)
FCF Yield = 7.43% (FCF TTM 18.7m / Enterprise Value 251.8m)
FCF Margin = 2.02% (FCF TTM 18.7m / Revenue TTM 925.3m)
Net Margin = 1.16% (Net Income TTM 10.8m / Revenue TTM 925.3m)
Gross Margin = 78.29% ((Revenue TTM 925.3m - Cost of Revenue TTM 200.9m) / Revenue TTM)
Gross Margin QoQ = 88.77% (prev 73.45%)
Tobins Q-Ratio = 0.34 (Enterprise Value 251.8m / Total Assets 742.9m)
Interest Expense / Debt = 0.88% (Interest Expense 123.0k / Debt 14.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = 43.7m (EBIT 55.3m * (1 - 21.00%))
Current Ratio = 2.24 (Total Current Assets 288.4m / Total Current Liabilities 128.6m)
Debt / Equity = 0.03 (Debt 14.0m / totalStockholderEquity, last quarter 533.1m)
Debt / EBITDA = -1.52 (Net Debt -144.4m / EBITDA 95.0m)
Debt / FCF = -7.72 (Net Debt -144.4m / FCF TTM 18.7m)
Total Stockholder Equity = 530.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.44% (Net Income 10.8m / Total Assets 742.9m)
RoE = 2.03% (Net Income TTM 10.8m / Total Stockholder Equity 530.5m)
RoCE = 10.43% (EBIT 55.3m / Capital Employed (Equity 530.5m + L.T.Debt 0.0))
RoIC = 8.13% (NOPAT 43.7m / Invested Capital 537.3m)
WACC = 9.34% (E(396.1m)/V(410.1m) * Re(9.65%) + D(14.0m)/V(410.1m) * Rd(0.88%) * (1-Tc(0.21)))
Discount Rate = 9.65% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.50%
[DCF] Terminal Value 70.73% ; FCFF base≈37.5m ; Y1≈32.6m ; Y5≈26.0m
[DCF] Fair Price = 28.46 (EV 375.9m - Net Debt -144.4m = Equity 520.3m / Shares 18.3m; r=9.34% [WACC]; 5y FCF grow -16.00% → 2.90% )
EPS Correlation: -59.65 | EPS CAGR: -15.93% | SUE: 0.51 | # QB: 0
Revenue Correlation: -54.16 | Revenue CAGR: -4.88% | SUE: 0.04 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.44 | Chg7d=+0.040 | Chg30d=+0.040 | Revisions Net=-1 | Analysts=1
EPS current Year (2026-12-31): EPS=2.00 | Chg7d=+0.160 | Chg30d=+0.050 | Revisions Net=-1 | Growth EPS=+3.6% | Growth Revenue=+1.8%
EPS next Year (2027-12-31): EPS=2.77 | Chg7d=+0.000 | Chg30d=-0.040 | Revisions Net=+1 | Growth EPS=+38.5% | Growth Revenue=+6.2%